SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-069123
Filing Date
2024-03-15
Accepted
2024-03-15 16:05:59
Documents
14
Period of Report
2024-03-15
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d650653d8k.htm   iXBRL 8-K 24619
  Complete submission text file 0001193125-24-069123.txt   143349

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA akba-20240315.xsd EX-101.SCH 2835
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE akba-20240315_lab.xml EX-101.LAB 17235
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akba-20240315_pre.xml EX-101.PRE 10802
16 EXTRACTED XBRL INSTANCE DOCUMENT d650653d8k_htm.xml XML 3539
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 24754718
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)